Skip to main content
Journal ArticleOPEN ACCESS

The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma

Clinical Infectious Diseases (2016) 63(11) 1490-1493
DOI: 10.1093/cid/ciw539
229Citations
Citations of this article
137Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

Author supplied keywords

Cite

CITATION STYLE

APA

Del Castillo, M., Romero, F. A., Argüello, E., Kyi, C., Postow, M. A., & Redelman-Sidi, G. (2016). The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clinical Infectious Diseases, 63(11), 1490–1493. https://doi.org/10.1093/cid/ciw539

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free